<SEC-DOCUMENT>0001171843-21-008671.txt : 20211222
<SEC-HEADER>0001171843-21-008671.hdr.sgml : 20211222
<ACCEPTANCE-DATETIME>20211222164113
ACCESSION NUMBER:		0001171843-21-008671
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20211222
FILED AS OF DATE:		20211222
DATE AS OF CHANGE:		20211222

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NOVARTIS AG
		CENTRAL INDEX KEY:			0001114448
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			V8
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-15024
		FILM NUMBER:		211513767

	BUSINESS ADDRESS:	
		STREET 1:		LICHTSTRASSE 35
		CITY:			BASEL
		STATE:			V8
		ZIP:			CH 4056
		BUSINESS PHONE:		01141613241111

	MAIL ADDRESS:	
		STREET 1:		LICHTSTRASSE 35
		CITY:			BASEL
		STATE:			V8
		ZIP:			CH 4056
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>f6k_122221.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>

</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font-size: 18pt; text-align: center; margin: 0pt 0"><B>UNITED STATES</B></P>

<P STYLE="font-size: 18pt; text-align: center; margin: 0pt 0"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Washington, D.C. 20549</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 18pt; text-align: center; margin: 0pt 0"><B>FORM 6-K</B></P>

<P STYLE="font-size: 18pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>REPORT OF FOREIGN PRIVATE ISSUER</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>PURSUANT TO RULE 13a-16 or 15d-16 OF</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Report on Form 6-K dated December 22, 2021</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>(Commission File No. 1-15024)</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">____________________</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 18pt; text-align: center; margin: 0pt 0"><B>Novartis AG</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">(Name of Registrant)</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Lichtstrasse 35</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>4056 Basel</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Switzerland</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">(Address of Principal Executive Offices)</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">____________________</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 3pt">Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: right; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Form 20-F:&nbsp;&#9746;</B></FONT></TD>
    <TD STYLE="width: 3%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 47%; font-size: 10pt"><FONT STYLE="font-size: 10pt">Form 40-F:&nbsp;&#9744;</FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 3pt">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1):</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: right"><FONT STYLE="font-size: 10pt">Yes:&nbsp;&#9744;</FONT></TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 47%"><FONT STYLE="font-size: 10pt"><B>No</B>:&nbsp;<B>&#9746;</B></FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 3pt">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7):&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: right"><FONT STYLE="font-size: 10pt">Yes:&nbsp;&#9744;</FONT></TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 47%"><FONT STYLE="font-size: 10pt"><B>No</B>:&nbsp;<B>&#9746;</B></FONT></TD></TR>
</TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0 3pt">Indicate by check mark whether the registrant by furnishing the information contained
in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange
Act of 1934.&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: right"><FONT STYLE="font-size: 10pt">Yes:&nbsp;&#9744;</FONT></TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 47%"><FONT STYLE="font-size: 10pt"><B>No</B>:&nbsp;<B>&#9746;</B></FONT></TD></TR>
</TABLE>


<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="color: rgb(0, 0, 0); font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="color: rgb(0, 0, 0); font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px"><FONT STYLE="font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 33%"><FONT STYLE="font-size: 10pt"><IMG SRC="logo.jpg" ALT=""></FONT></TD>
    <TD STYLE="width: 34%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 33%"><p style="color: rgb(4,96,169); font: 9pt Arial, Helvetica, Sans-Serif; margin: 0pt 0"><b>Novartis&nbsp;International&nbsp;AG<BR>
                           Novartis&nbsp;Global Communications</b><BR>
                           <font style="color: windowtext">CH-4002 Basel</font><BR>
                           <font style="color: windowtext">Switzerland</font></P>

<p style="color: #0460A9; font: bold 9pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">&nbsp;</P>

<p style="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">http://www.novartis.com</P>
<P STYLE="font: 9pt Arial, Helvetica, Sans-Serif; margin: 0pt 0">https://twitter.com/novartisnews</P>



</TD></TR>
</TABLE>
<P STYLE="color: rgb(0, 0, 0); font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px"><FONT STYLE="font-size: 10pt">&nbsp;</font></p>

<p style="color: rgb(0, 0, 0); font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px"><font style="font-size: 10pt">&nbsp;</font></p>

<p style="font: 14pt Arial, Helvetica, Sans-Serif; margin: 0pt 0; color: rgb(141,31,27)"><b>MEDIA &amp; INVESTOR RELEASE</b></p>

<P STYLE="color: rgb(0, 0, 0); font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="color: rgb(0, 0, 0); font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px"><font style="font-size: 10pt">&nbsp;</font></p>

<P STYLE="font-size: 18pt; margin: 0pt 0">FDA approves Novartis Leqvio&reg; (inclisiran), first-in-class siRNA to lower cholesterol and
keep it low with two doses a year</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt"><B>Ad hoc announcement pursuant to Art. 53 LR</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top"><TD STYLE="width: 20px"></TD><TD STYLE="width: 20px">&#8226;</TD><TD><I>With
two maintenance doses a year, Leqvio is the first and only FDA-approved small interfering RNA (siRNA) therapy for LDL-C (bad cholesterol)
reduction<SUP>1</SUP></I></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top"><TD STYLE="width: 20px"></TD><TD STYLE="width: 20px">&#8226;</TD><TD><I>Leqvio
provides effective and sustained LDL-C reduction of up to 52% vs. placebo for certain people with atherosclerotic cardiovascular disease
(ASCVD) on maximally tolerated statin therapy<SUP>2,3</SUP></I></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top"><TD STYLE="width: 20px"></TD><TD STYLE="width: 20px">&#8226;</TD><TD><I>Approximately
16 million Americans with ASCVD taking statins to lower cholesterol&mdash;including those who have experienced a heart attack or stroke&mdash;are
not at recommended LDL-C target<SUP>4,5</SUP></I></TD></TR></TABLE>


<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt"><B>Basel,&nbsp;December 22, 2021</B>&nbsp;&mdash; Novartis today announced the US Food and Drug
Administration (FDA) approval of Leqvio<SUP>&reg;</SUP>&nbsp;(inclisiran), the first and only small interfering RNA (siRNA) therapy to
lower low-density lipoprotein cholesterol (also known as bad cholesterol or LDL-C) with two doses a year, after an initial dose and one
at three months.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&ldquo;Leqvio is a revolutionary approach to lower LDL-C, and creates new possibilities for
how healthcare systems can impact cardiovascular disease, a defining public health challenge of our time,&rdquo; said Vas Narasimhan,
Novartis CEO. &ldquo;We now have the opportunity, working together with partners, to provide this first-ever approved LDL-C&ndash;lowering
siRNA-based therapy to tackle ASCVD at scale across the United States.&rdquo;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">Leqvio is indicated in the United States as an adjunct to diet and maximally tolerated statin
therapy for the treatment of adults with clinical atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia
(HeFH) who require additional lowering of LDL-C. The effect of Leqvio on cardiovascular morbidity and mortality is being explored in clinical
trials currently underway.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&ldquo;ASCVD is a substantial public health burden affecting 30 million Americans,&rdquo; said Norman Lepor, MD, a Los Angeles based cardiologist
and a clinical investigator in the Phase III clinical program for Leqvio. &ldquo;As a first-of-its-kind siRNA therapy, Leqvio works differently
than other cholesterol treatments, with twice-yearly dosing that makes it a compelling option for the millions of people with ASCVD already
on cholesterol-lowering medications struggling to reach their LDL-C target.&rdquo;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Leqvio reduces the amount of LDL-C in the bloodstream by improving the liver&rsquo;s natural
ability to prevent the production of a protein that plays a role in keeping circulating cholesterol levels high<SUP>6,7</SUP>. It is a
subcutaneous injection given by a healthcare provider with an initial dose, then again at three months, and then every six months<SUP>1</SUP>.
This approach may help those who have trouble sticking to medicines that are self-administered and have greater dosing frequency. Leqvio
will be available in early January 2022.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt">&ldquo;People with ASCVD have most likely experienced a heart attack or stroke from high cholesterol,
causing a burden on the family and having a negative impact on lives,&rdquo; said Andrea Baer, Executive Director of The Mended Hearts,
Inc. &ldquo;One of the first steps to improving patients&rsquo; health is to manage high cholesterol and we&rsquo;re encouraged that this
new twice-a-year treatment offers a new option.&rdquo;&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The FDA approval was based on results from the comprehensive Phase III ORION-9, -10 and -11
clinical trials, in which all 3,457 participants with ASCVD or HeFH had elevated LDL-C while receiving a maximally tolerated dose of statin
therapy<SUP>2,3</SUP>. In the Phase III trials at month 17, Leqvio delivered effective and sustained LDL-C reduction of up to 52% vs.
placebo and was reported to be well-tolerated with a safety profile shown to be comparable to placebo<SUP>2,3</SUP>. The most common side
effects were mild to moderate injection site reaction (including pain, redness and rash), joint pain, urinary tract infection, diarrhea,
chest cold, pain in legs or arms and shortness of breath<SUP>2,3</SUP>.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Novartis has obtained global rights to develop, manufacture and commercialize Leqvio under a
license and collaboration agreement with Alnylam Pharmaceuticals, a leader in RNAi therapeutics.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Disclaimer</B><BR>
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act
of 1995. Forward-looking statements can generally be identified by words such as &ldquo;will,&rdquo; &ldquo;may,&rdquo; &ldquo;believe,&rdquo;
&ldquo;keep,&rdquo; &ldquo;taking on,&rdquo; next-generation,&rdquo; &ldquo;enables,&rdquo; &ldquo;to explore,&rdquo; &ldquo;innovative,&rdquo;
&ldquo;to help,&rdquo; &ldquo;improving,&rdquo; &ldquo;keeping,&rdquo; &ldquo;to develop,&rdquo; &ldquo;possible,&rdquo; &ldquo;goal,&rdquo;
or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for Leqvio,
or regarding potential future revenues from Leqvio. You should not place undue reliance on these statements. Such forward-looking statements
are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and
uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual
results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that Leqvio will be submitted
or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee
that Leqvio will be successfully launched in the markets where it is approved, or at any particular time. Neither can there be any guarantee
that Leqvio will be commercially successful in the future. In particular, our expectations regarding Leqvio could be affected by, among
other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing
clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including
government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability
to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients;
general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases such as COVID-19;
safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of
our information technology systems, and other risks and factors referred to in Novartis AG&rsquo;s current Form 20-F on file with the
US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake
any obligation to update any forward-looking statements contained in this press release as a result of new information, future events
or otherwise.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt"><B>About Novartis in cardiovascular renal metabolism</B><BR>
Cardiovascular (CV), renal and metabolic diseases are a global health crisis<SUP>8-11</SUP>.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">These chronic, complex and often hereditary diseases are frequently inter-related, and come
with healthcare and treatment barriers and a lack of transformative medicines, and almost always lead to the same outcome: death due to
CV disease<SUP>8-11</SUP>.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">CV disease is the number one killer in the world<SUP>8</SUP>. Taking more lives than all cancers
combined, it contributes to one in every three deaths globally<SUP>8,12</SUP>. Of all CV events, 80% can be prevented<SUP>13</SUP>. Patients
and their families deserve better, and our society deserves more.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Thanks to a combination of our legacy, global footprint and leading science, Novartis is uniquely
positioned to help change this landscape. We are transforming the way we think about the relationship between these diseases and how they
are managed throughout life. Our efforts include the use of early interventions and the development of pioneering treatments that address
the spectrum of CV, renal and metabolic diseases, from prevention to management, as well as the creation of innovative access models.
By re-writing the way we work with society, we will lead a worldwide effort to improve health outcomes and roll back the crisis of CV
death.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Our goal is to bend the curve of life by reducing and stopping premature death from CV disease.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>About Novartis</B><BR>
Novartis is reimagining medicine to improve and extend people&rsquo;s lives. As a leading global medicines company, we use innovative
science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines,
we consistently rank among the world&rsquo;s top companies investing in research and development. Novartis products reach nearly 800
million people globally and we are finding innovative ways to expand access to our latest treatments. About 108,000 people of more than
140 nationalities work at Novartis around the world. Find out more at&nbsp;https://www.novartis.com.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Novartis is on Twitter. Sign up to follow @Novartis at&nbsp;<B>https://twitter.com/novartisnews</B><BR>
For Novartis multimedia content, please visit&nbsp;<B>https://www.novartis.com/news/media-library</B><BR>
For questions about the site or required registration, please contact&nbsp;media.relations@novartis.com</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>References</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top"><TD STYLE="width: 20px"></TD><TD STYLE="width: 20px">1.</TD><TD>Leqvio
                                            prescribing information. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2021. &nbsp;&nbsp;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top"><TD STYLE="width: 20px"></TD><TD STYLE="width: 20px">2.</TD><TD>Ray
                                            KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated
                                            LDL cholesterol.&nbsp;<I>N Engl J Med</I>. 2020;382(16):1507-1519. doi:10.1056/NEJMoa1912387</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top"><TD STYLE="width: 20px"></TD><TD STYLE="width: 20px">3.</TD><TD>Raal
                                            FJ, Kallend D, Ray KK, et al. Inclisiran for heterozygous familial hypercholesterolemia.&nbsp;<I>N
                                            Engl J Med</I>. 2020;382(16):1520-1530. doi:10.1056/NEJMoa1913805</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top"><TD STYLE="width: 20px"></TD><TD STYLE="width: 20px">4.</TD><TD>Wong
                                            ND, Young D, Zhao Y, et al. Prevalence of the American College of Cardiology/American Heart
                                            Association statin eligibility groups, statin use, and low-density lipoprotein cholesterol
                                            control in US adults using the National Health and Nutrition Examination Survey 2011-2012.&nbsp;<I>J
                                            Clin Lipidol</I>. 2016;10(5):1109-1118. doi: 10.1016/j.jacl.2016.06.011</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top"><TD STYLE="width: 20px"></TD><TD STYLE="width: 20px">5.</TD><TD>Grundy
                                            MS, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/ AGS/APhA/ASPC/NLA/PCNA
                                            Guideline on the Management of Blood Cholesterol: a report of the American College of Cardiology/American
                                            Heart Association Task Force on Clinical Practice Guidelines.&nbsp;<I>Circulation.</I>&nbsp;2019;139:e1082&ndash;e1143.
                                            doi: 10.1161/CIR.0000000000000625</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top"><TD STYLE="width: 20px"></TD><TD STYLE="width: 20px">6.</TD><TD>Khvorova
                                            A. Oligonucleotide therapeutics&mdash;a new class of cholesterol-lowering drugs.&nbsp;<I>N
                                            Engl J Med</I>. 2017;376(1):4-7. doi: 10.1056/NEJMp1614154</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top"><TD STYLE="width: 20px"></TD><TD STYLE="width: 20px">7.</TD><TD>Kosmas
                                            CE, Mu&ntilde;oz Estrella A, Sourlas A, et al. Inclisiran: a new promising agent in the management
                                            of hypercholesterolemia.&nbsp;<I>Diseases</I>. 2018;6(3):63. doi: 10.3390/diseases6030063</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top"><TD STYLE="width: 20px"></TD><TD STYLE="width: 20px">8.</TD><TD>World
                                            Health Organization. Cardiovascular diseases (CVDs). June 11, 2021. Accessed November 23,
                                            2021.&nbsp;https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top"><TD STYLE="width: 20px"></TD><TD STYLE="width: 20px">9.</TD><TD>National
                                            Kidney Foundation. Global Facts: About Kidney Disease. Accessed November 23, 2021.&nbsp;https://www.kidney.org/kidneydisease/global-facts-about-kidney-disease</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top"><TD STYLE="width: 20px"></TD><TD STYLE="width: 20px">10.</TD><TD>Levey
                                            AS, Atkins R, Coresh J, et al. Chronic kidney disease as a global public health problem:
                                            approaches and initiatives&mdash;a position statement from Kidney Disease Improving Global
                                            Outcomes.&nbsp;<I>Kidney Int.</I>&nbsp;2007;72(3):247-259. doi: 10.1038/sj.ki.5002343</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top"><TD STYLE="width: 20px"></TD><TD STYLE="width: 20px">11.</TD><TD>World
                                            Health Organization. Diabetes. November 10, 2021. Accessed November 23, 2021.&nbsp;https://www.who.int/news-room/fact-sheets/detail/diabetes</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top"><TD STYLE="width: 20px"></TD><TD STYLE="width: 20px">12.</TD><TD>American Cancer Society.&nbsp;<I>Global Cancer Facts &amp; Figures 4th Edition</I>. Atlanta, GA: American Cancer Society; 2018.
                                                                                                                                                                         Accessed November 23, 2021.
                                                                                                                                                                         https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-4th-edition.pdf</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top"><TD STYLE="width: 20px"></TD><TD STYLE="width: 20px">13.</TD><TD>World Health Organization. Cardiovascular diseases: Data and statistics.&nbsp;Accessed November 23, 2021.
                                                                                                                                                                         https://www.euro.who.int/en/health-topics/noncommunicable-diseases/cardiovascular-diseases/data-and-statistics</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"># # #</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Novartis Media Relations</B><BR>
E-mail:&nbsp;media.relations@novartis.com</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-size: 10pt">Jamie Bennett<BR>
    Director, US External Engagement<BR>
    +1 862 217 3976<BR>
    jamie.bennett@novartis.com<BR>
    &nbsp;<BR>
    Julie Masow<BR>
    Novartis US External Communications<BR>
    +1 862 579 8456<BR>
    julie.masow@novartis.com<BR>
    &nbsp;</FONT></TD>
    <TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-size: 10pt">Phil McNamara<BR>
    Global Head, Novartis Cardio-Renal-Metabolic Communications<BR>
    +41 79 510 8756 (mobile)<BR>
    philip.mcnamara@novartis.com<BR>
    &nbsp;</FONT></TD></TR>
  </TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt"><B>Novartis Investor Relations</B><BR>
Central investor relations line: +41 61 324 7944<BR>
E-mail:&nbsp;investor.relations@novartis.com</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%"><FONT STYLE="font-size: 10pt">Central</FONT></TD>
    <TD STYLE="width: 21%">&nbsp;</TD>
    <TD STYLE="width: 28%"><FONT STYLE="font-size: 10pt">North America</FONT></TD>
    <TD STYLE="width: 21%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Samir Shah</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">+41 61 324 7944</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Sloan Simpson</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">+1 862 345 4440</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Thomas Hungerbuehler</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">+41 61 324 8425</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Alina Levchuk</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">+1 862 778 3372</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Isabella Zinck</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">+41 61 324 7188</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Parag Mahanti</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">+1 973-876-4912</FONT></TD></TR>
  </TABLE>
<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"># # #</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<p style="color: rgb(0, 0, 0); font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px"><font style="font-size: 10pt">&nbsp;</font></p>

<p style="color: rgb(0, 0, 0); font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px"><font style="font-size: 10pt">&nbsp;</font></p>

<p style="color: rgb(0, 0, 0); font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px"><font style="font-size: 10pt">&nbsp;</font></p>

<p style="color: rgb(0, 0, 0); font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px"><font style="font-size: 10pt">&nbsp;</font></p>

<p style="color: rgb(0, 0, 0); font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px"><font style="font-size: 10pt">&nbsp;</font></p>

<p style="color: rgb(0, 0, 0); font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px"><font style="font-size: 10pt">&nbsp;</font></p>

<p style="color: rgb(0, 0, 0); font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px"><font style="font-size: 10pt">&nbsp;</font></p>

<p style="color: rgb(0, 0, 0); font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px"><font style="font-size: 10pt">&nbsp;</font></p>

<p style="color: rgb(0, 0, 0); font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px"><font style="font-size: 10pt">&nbsp;</font></p>

<p style="color: rgb(0, 0, 0); font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px"><font style="font-size: 10pt">&nbsp;</font></p>

<p style="color: rgb(0, 0, 0); font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px"><font style="font-size: 10pt">&nbsp;</font></p>

<p style="color: rgb(0, 0, 0); font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px"><font style="font-size: 10pt">&nbsp;</font></p>

<p style="color: rgb(0, 0, 0); font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px"><font style="font-size: 10pt">&nbsp;</font></p>

<p style="color: rgb(0, 0, 0); font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px"><font style="font-size: 10pt">&nbsp;</font></p>

<p style="color: rgb(0, 0, 0); font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px"><font style="font-size: 10pt">&nbsp;</font></p>

<p style="color: rgb(0, 0, 0); font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px"><font style="font-size: 10pt">&nbsp;</font></p>

<p style="color: rgb(0, 0, 0); font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px"><font style="font-size: 10pt">&nbsp;</font></p>

<p style="color: rgb(0, 0, 0); font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px"><font style="font-size: 10pt">&nbsp;</font></p>

<p style="color: rgb(0, 0, 0); font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px"><font style="font-size: 10pt"><font style="color: Black"><b>&nbsp;</b></font></font></P>

<P STYLE="font-size: 10pt; margin: 0.45pt 0 0"></P>

<P STYLE="font-size: 10pt; margin: 0.55pt 0 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0.55pt 0 0">&nbsp;</P>


<P STYLE="color: rgb(0, 0, 0); font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"></FONT></P>

<P STYLE="color: rgb(0, 0, 0); font-size: 12pt; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0px"><FONT STYLE="font-size: 10pt">&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></FONT></P>



<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 5 -->
    <div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 4pt solid">&nbsp;</div>
    <div style="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></div>
    <!-- Field: /Page -->

<p style="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to
the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; background-color: white; font-size: 10pt">
<TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Novartis AG</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD STYLE="width: 52%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 7%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 16%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: December 22, 2021</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ PAUL
    PENEPENT</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul Penepent</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Head Group Financial Reporting and
    Accounting</FONT></TD></TR>
</TABLE>


<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0"><font style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</font></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#F17AI9@  34T *@    @ !0$.  (
M   6   (5@$Q  (    F   (;(=I  0    !   (DIR;  $    L   0LNH<
M  <   @,    2@     <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M     &YO=F%R=&ES7VQO9V]?<F=B7W!O<P!!9&]B92!);&QU<W1R871O<B!#
M0R R,#$U("A-86-I;G1O<V@I   !ZAP !P  " P   BD     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                      !N &\ =@!A '( = !I ',
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MS_\ $ITHL.C$+)<./?'EK^+5^79S.69Y_0R^'PTVI2_/\K6\V?T9PI2I\/\
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M!GPBWB2[^'/B+Q=X9M[9I]2U31'M3'8 ''[U9)D?&#G<JD>I%>VU\[_M:?\
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M#?0?@UXZU+QQIC3K?Z2@T]9(# X24%FN@GRL0.&/7C->C:=^T2__  OSP/\
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M<T:RQMU5UR#^!HHJ2AP 50J@*HZ 4M%% !1110 4444 %%%% !1110 4444
M%%%% !6;J&CZ1J\(CU;2K/5(QT6[MDE _!@:**:;3NA-)JS':?I6EZ19FWTG
:3;72[<G)BM+=8E_)0!6A110VV[L$DE9'_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
